SECUKINUMAB 150MG

                      Anti Cancer Drug-secukinimab 150mg

Secukinimab(scapho) 150mg:

scapho 150mg

product details:

Composition : Secukinumab

Strength availability : 150mg

Form : injection

Pack : 150mg in 1 vial

Description:

Secukinumab belongs to monoclonal antibody which is a protein which recognises and connect to an inflammatory protein called Interleukin 17A (IL-17A). In patients with psoriatic arthritis and ankylosing spondylitis, the body’s immune system produces an increased amount of IL-17A which causes the symptoms such as swollen and painful joints
Scapho 150mg is a prescription drugs which is used under proper guidance of medical oncologist

INDICATION:

Scapho 150mg indicated for the treatment of following condition

Plaque Psoriasis

Psoriatic arthritis

Ankylosing spondylitis.

DOSAGE:

dosage

Plaque Psoriasis:

Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, administer 300 mg SC once monthly
For some patientsmay be acceptable containing dose of 150 mg
Psoriatic Arthritis : Indicated for adults with active psoriatic arthritis
Recommended dosage
Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
Scapho 150mg with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho 150mg without loading dose administrated 150 mg SC q4wk.
Consider a dosage of 300 mg, if a patient continues to have active psoriatic arthritis
May be administered with or without methotrexate.

Ankylosing Spondylitis:

Given with or without a loading dosage by SC injection
Scapho 150mg with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho 150mg without a loading dose is administrated150 mg SC q4wk

MECHANISM:

Secukinumab 150mg mechanism as Interleukin-17A (IL-17A) is a cornerstone cytokine (messenger protein) contains in the development of psoriasis and is found in peak concentrations in psoriasis plaques.
Secukinumab 150mg consist of human IgG1 monoclonal antibody which selectively binds to IL-17A, rapidly prohibiting its pro-inflammatory effects.

ADME

Maximum plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days
Volume of distribution is 7.1 – 8.6 (IV administration)
The drug scapho 150mg is Metabolized via intracellular catabolism.
Scapho 150mg has half-life is 22-31 days

PRECAUTION:

precaution

Scapho 150mg may have high risk of infections; use with caution in patients with chronic infection or a history of recurrent infection
Before to initiation of scapho 150mg,start with anti-TB therapy in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed
May infuriate Crohn disease
Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho 150mg immediately and start anaphylaxis treatment

DRUG INTERACTION

Live vaccinations combination with Scapho 150mg should be avoided
CYP450 substrates concomitant use with Scapho 150mg injection may altered by increased levels of certain cytokines.

CONTRAINDICATION

Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients

STORAGE:

Store the Scapho 150mg at 2℃ to 8℃.

MISSED DOSE

In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them.
thereby missed dose should be avoid and follow the regular dosing schedule.

SIDE EFFECTS

• Infections

• Nasopharyngitis

• Diarrhea 

• URT infection 

• Rhinitis 

• Oral herpes 

• Pharyngitis 

• Urticaria 

• Rhinorrhoea

Contact Details:

Phone :+91-9987711567

Email :applepharmaceutical@gmail.com

Email :info@myapplepharma.com